What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? [PDF]
, 2017 AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF).
Clark, Andrew L. +8 more
core +3 more sources
Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism? [PDF]
, 2022 Little is known about the mechanism underlying Sacubitril/Valsartan effects in patients with heart failure (HFrEF). Aim of the study is to assess hemodynamic vs.
Agostoni, Piergiuseppe +18 more
core +2 more sources
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]
, 2016 AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian +12 more
core +1 more source
Sakubitriili ja valsartaani kombinatsioon südamepuudulikkuse ravis Eestis [PDF]
, 2018 Eesti Arst 2018; 97(2):95 ...
Irs, Alar
core +2 more sources
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
Budget Impact Analysis of Sacubitril Valsartan in the Treatment of Heart Failure and Reduced Ejection Fraction (HFrEF) in Indonesia [PDF]
, 2022 Based on PARADIGM-HF Clinical Trials, LCZ696 a dual-acting sodium supramolecular complex currently known as sacubitril/valsartan was superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF) in patients with heart ...
Endarti, Dwi +4 more
core +2 more sources
MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation
ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio +10 more
wiley +1 more source
Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca
Revista Portuguesa de Cardiologia, 2017 Resumo: O sacubitril/valsartan (LCZ696) é um complexo supramolecular de sal de sódio do pró‐fármaco sacubitril, inibidor da neprilisina, e do valsartan, um antagonista dos recetores da angiotensina (ARB), administrado por via oral, recentemente aprovado ...
Pedro Marques da Silva, Carlos Aguiar
doaj +1 more source
From ARB to ARNI in Cardiovascular Control [PDF]
, 2016 Coexistence of hypertension, diabetes mellitus and chronic kidney disease synergistically aggravates the risk of cardiovascular and renal morbidity and mortality.
Danser, A.H.J. (Jan) +3 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source